Abstract
Background
The EQ-5D-5L questionnaire is used in oncology to generate health-related quality of life (HRQoL) weights and corresponding health states. The purpose was to explore the relationship between demographic and clinical characteristics and HRQoL among advanced or metastatic colorectal cancer (CRC) patients by linking clinical data of a German CRC registry to self-reported HRQoL measures from the EQ-5D-5L.
Methods
The study sample included patients with advanced or metastatic CRC currently recruited in the German Tumor Registry Colorectal Cancer. The EQ-5D-5L was administered once to patients who were at the start or at later stages of palliative treatment. Data on comorbidities, disease-specific health states, symptoms, and treatment status were drawn from the registry. Multivariate regression analyses were performed to explore the impact of patient and disease characteristics on HRQoL.
Results
In total, n = 433 questionnaires were included in the data analysis. Mean age of patients was 66.3 years and 61.2% were male. The mean EQ-5D-5L utility score was 0.82 and the mean EQ-5D-5L VAS score was 62.05. The regression analyses revealed that none of the demographic characteristics and few of the clinical characteristics, such as fatigue and pain, had a significant impact on the HRQoL.
Conclusions
The study demonstrated a reduced HRQoL of patients with advanced or metastatic CRC when compared to the general population. The symptoms fatigue and pain negatively affected the HRQoL, whereas other characteristics such as age, gender, and comorbidities did not have a significant impact on HRQoL.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Jacob, Christian 1 ; Wetzel, Natalie 2 ; Jänicke Martina 2 ; Eggers Egbert 3 ; Sauer, Annette 4 ; Marschner Norbert 5 ; Altevers Julia 6 ; Mittendorf, Thomas 6 ; Greiner, Wolfgang 7 1 Xcenda GmbH, Hannover, Germany
2 iOMEDICO AG, Freiburg im Breisgau, Germany (GRID:grid.476932.d)
3 Kreiskrankenhaus Torgau, Torgau, Germany (GRID:grid.476932.d)
4 Medizinisches Versorgungszentrum für Blut- und Krebserkrankungen, Potsdam, Germany (GRID:grid.476932.d)
5 Praxis für interdisziplinäre Onkologie und Hämatologie, Freiburg im Breisgau, Germany (GRID:grid.476932.d)
6 Xcenda GmbH, Hannover, Germany (GRID:grid.476932.d)
7 Universität Bielefeld, Bielefeld, Germany (GRID:grid.7491.b) (ISNI:0000 0001 0944 9128)




